Appili Therapeutics

Exhibitor

Appili Therapeutics is a biopharmaceutical company that is purpose‑built, portfolio‑driven, and people‑focused to solve life‑threatening infections. By systematically identifying urgent infections with unmet needs, Appili aims to strategically develop a pipeline of novel therapies and vaccines to prevent deaths and improve lives, while leveraging deep expertise in securing non‑dilutive funding.

The Company is advancing a diverse range of anti‑infectives, including an FDA‑approved ready‑made suspension of metronidazole for antimicrobial‑resistant infections, a vaccine candidate to prevent tularemia, a serious biological weapon threat, a topical antiparasitic for cutaneous leishmaniasis, and VXV‑01, a collaboratively developed vaccine targeting invasive fungal infections. Led by a proven management team, Appili is at the center of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

website